Cardizem CD: Para IV For An Age Old Compound, Still Enjoys Limited Competition
Our recent study about the Cardizem CD Para IV litigation between Sun Pharma and Valeant (erstwhile Biovail) leads us to conclude that (1) this could be a lucrative low competition opportunity for Sun Pharma till August 2012 (2) there is currently no competition for 360mg Cardizem CD and Sun Pharma will be the only generic competition for this version. Biovail (now Valeant) and Sun Pharma has already settled this litigation whereby Sun will be able to launch the generic of Cardizem CD upon receiving final USFDA approval including the launch of 360mg. Sun will also have to pay some royalty on the net sales till 8 Aug 2012 – the date of final patent expiry of Cardizem CD.
COMPANIES MENTIONED
SUN PHARMA, SUNP
SUN PHARMA, SUNP
